Every effective medication comes with side effects. Retatrutide — the most powerful weight loss drug ever tested — is no exception. This article provides a thorough, data-driven analysis of retatrutide's side effect profile based on published Phase 2 clinical trial data, with practical guidance on what to expect and how these effects compare to existing medications.
Key Takeaways
- GI side effects dominate — nausea (25%), diarrhoea (23%), vomiting (13%), and constipation (12%) at the 12 mg dose
- Side effects are dose-dependent — higher doses produce more GI symptoms but also more weight loss
- Most symptoms are transient — they peak during dose escalation and diminish over time
- Discontinuation rates are low — only ~6% of participants stopped treatment due to side effects at higher doses
- The glucagon component introduces unique considerations: modest heart rate increase (2–4 bpm) and slightly more diarrhoea than GLP-1-only drugs
- Overall safety profile is comparable to tirzepatide (Mounjaro) and semaglutide (Ozempic), with no unexpected serious safety signals
Medical Disclaimer: Retatrutide is an investigational drug not yet approved by any regulatory authority. The side effect data presented here is from Phase 2 clinical trials with 338 participants. Phase 3 trials with thousands of participants may reveal additional side effects or change the frequency estimates below. This article is for informational purposes only — always consult a healthcare professional.
Overview of Retatrutide's Side Effect Profile
Retatrutide's side effects are broadly similar to other GLP-1 receptor agonist medications. If you've used Ozempic, Mounjaro, or Saxenda, many of these effects will be familiar. However, the glucagon receptor component introduces some nuances worth understanding.
The key principle to remember: retatrutide's side effects are overwhelmingly gastrointestinal, dose-dependent, and transient. They're uncomfortable but rarely dangerous, and they tend to improve as your body adapts to the medication.
Gastrointestinal Side Effects: The Complete Data
GI symptoms are the most common side effects across all GLP-1-based medications, and retatrutide is no exception. Here's the full Phase 2 data broken down by dose:
GI Side Effects by Dose Group
| Side Effect | Placebo | 1 mg | 4 mg | 8 mg | 12 mg |
|---|---|---|---|---|---|
| Nausea | 6% | 10% | 18% | 22% | 25% |
| Diarrhoea | 8% | 10% | 15% | 20% | 23% |
| Vomiting | 2% | 4% | 8% | 10% | 13% |
| Constipation | 6% | 6% | 8% | 10% | 12% |
| Decreased appetite | 2% | 4% | 6% | 8% | 9% |
| Dyspepsia | 2% | 2% | 4% | 5% | 5% |
| Abdominal pain | 4% | 4% | 5% | 5% | 6% |
The dose-response relationship is clear: higher doses = more side effects. This is also why all GLP-1 medications use a gradual dose escalation protocol — starting low and increasing over weeks gives your body time to adapt.
Nausea: The Most Common Side Effect
Nausea is the hallmark side effect of all GLP-1 drugs. With retatrutide at the 12 mg dose, approximately 1 in 4 participants experienced nausea. Important context:
- Timing: Most nausea occurs during the first 4–8 weeks of treatment, particularly during dose increases
- Severity: The majority of cases were rated as mild to moderate — uncomfortable but tolerable
- Duration: For most participants, nausea diminished significantly after the body adapted to each new dose level
- Management: Eating smaller meals, avoiding fatty/greasy foods, and staying hydrated helps. Anti-nausea medication (e.g., ondansetron) can be prescribed for more severe cases
For a comprehensive guide to managing GLP-1 nausea and other GI effects, see our Ozempic Side Effects Guide — the management strategies apply to all GLP-1-based drugs including retatrutide.
Diarrhoea: Slightly More Common Than Other GLP-1s
Diarrhoea was notably more common with retatrutide (23% at 12 mg) compared to semaglutide (~15–18%) and tirzepatide (~18%). This may be related to the glucagon component, which can increase gut motility and bile acid secretion.
For most patients, this was manageable and did not lead to discontinuation. Staying well-hydrated and adjusting diet (reduced fibre during dose escalation, avoiding trigger foods) typically helps.
Vomiting
Vomiting affected about 13% of participants at the highest dose. Like nausea, it was most common during dose escalation and tended to resolve. Persistent or severe vomiting warrants medical attention, as it can cause dehydration and electrolyte imbalances.
Constipation
While less discussed than nausea, constipation (12% at 12 mg) can be equally bothersome. GLP-1 receptor activation slows gastric emptying, which can reduce bowel movement frequency. Adequate hydration, fibre intake, and gentle physical activity are the first-line management strategies.
Glucagon-Specific Side Effects
The glucagon receptor component is what makes retatrutide unique — and it introduces some side effects not seen with GLP-1-only or GLP-1/GIP dual agonist drugs.
Heart Rate Increase
A modest increase in resting heart rate of 2–4 beats per minute (bpm) was observed in the Phase 2 trial. This is consistent with glucagon's known stimulatory effects on the cardiovascular system.
Important context:
- The increase was small and not considered clinically significant in the trial
- Semaglutide also causes a slight heart rate increase (~2 bpm), so this effect is not unique to retatrutide
- No cardiac arrhythmias or serious cardiovascular events were attributable to this effect in Phase 2
- The Phase 3 TRIUMPH-3 trial is specifically designed to evaluate cardiovascular safety in a large population over an extended period
For patients with pre-existing cardiac conditions (particularly tachyarrhythmias), this effect will need to be discussed with their cardiologist. For most healthy individuals with obesity, a 2–4 bpm increase is inconsequential.
Blood Glucose Dynamics
Glucagon naturally raises blood sugar — which might seem counterintuitive in a drug targeting metabolic health. However, in the Phase 2 trial:
- The GLP-1 and GIP components more than compensated for glucagon's glucose-raising effect
- Overall glucose control improved significantly in all dose groups
- HbA1c decreased by up to 1.3% in participants with type 2 diabetes
- No increased risk of hypoglycaemia (dangerously low blood sugar) was observed
The net effect on blood glucose is positive. However, patients with type 2 diabetes on insulin or sulfonylureas should be monitored carefully, as the combination could theoretically cause hypoglycaemia — a standard precaution with all GLP-1 medications.
Liver Enzyme Changes
Glucagon receptor activation affects liver metabolism, which could theoretically alter liver enzyme levels. In the Phase 2 trial:
- No clinically significant increases in ALT or AST (liver enzymes) were observed
- In fact, liver enzymes improved in most participants — consistent with the dramatic reduction in liver fat
- Regular liver function monitoring will likely be recommended in the prescribing information when retatrutide is approved
Comparison to Other GLP-1 Medications
How does retatrutide's side effect profile compare to medications you can get in Malaysia today?
| Side Effect | Semaglutide 2.4 mg (Wegovy) | Tirzepatide 15 mg (Mounjaro) | Retatrutide 12 mg |
|---|---|---|---|
| Nausea | 44% | 24% | 25% |
| Diarrhoea | 30% | 18% | 23% |
| Vomiting | 24% | 12% | 13% |
| Constipation | 24% | 11% | 12% |
| Heart rate increase | ~2 bpm | Minimal | ~2–4 bpm |
| Discontinuation due to AEs | ~7% | ~5% | ~6% |
Key insight: Retatrutide's GI side effect rates are remarkably similar to tirzepatide (Mounjaro) and actually lower than semaglutide (Wegovy/Ozempic) at equivalent efficacy levels. This is notable because retatrutide produces significantly more weight loss than both.
In other words, retatrutide offers a better efficacy-to-tolerability ratio than semaglutide — more weight loss with fewer side effects. Compared to tirzepatide, the side effect profile is nearly identical despite the addition of the glucagon mechanism.
For more on semaglutide side effects specifically, see our long-term semaglutide side effects guide.
Serious Adverse Events
No medication discussion is complete without addressing serious adverse events (SAEs). In the Phase 2 trial:
- Serious adverse events occurred in ~5% of participants across dose groups — similar to placebo rates
- No deaths were attributed to the study drug
- No cases of pancreatitis were reported (a theoretically possible risk with all GLP-1 drugs)
- No medullary thyroid carcinoma signals (the boxed warning on existing GLP-1 drugs, based on animal data)
- No significant gallbladder events — though rapid weight loss from any cause increases gallstone risk
However, Phase 2 trials are too small to detect rare events. With only 338 participants, an adverse event occurring in 1 in 1,000 patients would likely not appear. This is precisely why Phase 3 trials (thousands of participants) and post-marketing surveillance are essential.
Theoretical Risks to Monitor in Phase 3
Based on the mechanism of action and experience with related drugs, the following risks will be closely monitored in the TRIUMPH Phase 3 programme:
- Pancreatitis: A known class concern for all GLP-1 drugs (rare but serious)
- Thyroid C-cell tumours: GLP-1 agonists carry a boxed warning based on rodent studies; no human signal has been confirmed for any GLP-1 drug, but long-term monitoring continues
- Gallbladder disease: Rapid weight loss increases gallstone risk regardless of mechanism
- Cardiovascular events: The TRIUMPH-3 trial will provide definitive data; the heart rate increase needs long-term evaluation
- Retinopathy in diabetic patients: Rapid glucose improvement can temporarily worsen diabetic retinopathy (seen with semaglutide)
- Bone density: Significant weight loss may affect bone mineral density — particularly relevant for older patients
- Muscle mass loss: All weight loss interventions cause some lean mass loss; the ratio of fat loss to muscle loss is an important metric
Managing Retatrutide Side Effects: Practical Strategies
While retatrutide isn't available yet, the management strategies for its GI side effects will be identical to those used for existing GLP-1 medications. Here's what works:
Dietary Modifications
- Eat smaller, more frequent meals — 4–5 small meals instead of 2–3 large ones
- Avoid high-fat and greasy foods — these exacerbate nausea significantly
- Reduce portion sizes proactively — your appetite will decrease; eating to the point of fullness often triggers nausea
- Stay hydrated — sip water throughout the day, especially if experiencing diarrhoea or vomiting
- Bland foods during escalation — rice, toast, bananas, and congee are well-tolerated during the adjustment period
- Avoid carbonated drinks and alcohol during dose escalation
For a comprehensive meal plan designed around GLP-1 therapy, see our GLP-1 Diet Plan for Malaysia.
Timing and Administration
- Take your injection on a consistent day each week
- Some patients prefer injecting before bed — sleeping through the initial nausea window
- Inject on a lighter eating day — some patients choose a day when they don't have social meals planned
- Never skip dose escalation steps — jumping straight to higher doses dramatically worsens side effects
Medical Management
If dietary modifications aren't sufficient, your doctor may prescribe:
- Ondansetron (Zofran): An anti-nausea medication that can be used as needed during dose escalation
- Loperamide (Imodium): For managing diarrhoea episodes
- Fibre supplements: For constipation management
- Electrolyte solutions: If vomiting or diarrhoea leads to dehydration
When to Seek Medical Attention
Contact your doctor immediately if you experience:
- Severe, persistent vomiting that prevents keeping fluids down
- Severe abdominal pain (especially radiating to the back — possible pancreatitis sign)
- Signs of dehydration: dizziness, dark urine, rapid heartbeat, confusion
- Allergic reaction: rash, swelling, difficulty breathing
- Significant heart rate changes or palpitations
- Yellowing of skin or eyes (jaundice — possible liver issue)
What Phase 3 Will Tell Us About Safety
Phase 2 data gives us a preliminary safety picture, but Phase 3 trials are where the true safety profile emerges. The TRIUMPH programme will provide:
- Larger sample size: Thousands vs hundreds of participants — better detection of rare events
- Longer duration: 72+ weeks (vs 48 weeks in Phase 2) — revealing late-onset effects
- More diverse populations: Different ethnicities, ages, comorbidities — including Southeast Asian participants
- Cardiovascular outcomes: TRIUMPH-3 will definitively characterise cardiac safety
- Hepatic outcomes: TRIUMPH-4 will clarify liver effects in MASH patients
Until Phase 3 data is available, the side effect profile presented in this article should be considered preliminary. It provides a reasonable expectation but may be refined as more data emerges.
Frequently Asked Questions
Are retatrutide's side effects worse than Ozempic's?
Actually, the data suggests retatrutide may be better tolerated than semaglutide (Ozempic/Wegovy) at equivalent efficacy levels. Semaglutide 2.4 mg causes nausea in ~44% of patients; retatrutide 12 mg causes nausea in ~25%. However, cross-trial comparisons should be interpreted cautiously.
Do the side effects get better over time?
Yes. For the vast majority of patients, GI side effects are worst during the first few weeks of treatment and during dose increases. They typically diminish significantly once you reach your target dose and your body adapts. This pattern is consistent across all GLP-1 medications.
Will the glucagon component cause blood sugar problems?
No. Despite glucagon's glucose-raising effect, the GLP-1 and GIP components in retatrutide more than compensate. Overall glucose control improves with treatment. However, diabetic patients on insulin or sulfonylureas should be monitored for hypoglycaemia.
Is the heart rate increase dangerous?
The 2–4 bpm increase observed in Phase 2 is small and was not associated with any adverse cardiovascular events. For healthy individuals, this is inconsequential. Patients with cardiac conditions should discuss this with their cardiologist. Phase 3 will provide definitive cardiovascular safety data.
Should I wait for Phase 3 safety data before considering retatrutide?
You don't have a choice — retatrutide won't be available until after Phase 3 completion and regulatory approval (estimated 2029–2030 in Malaysia). By then, comprehensive safety data will be available. In the meantime, Ozempic and Mounjaro offer well-characterised safety profiles and excellent efficacy.
The Bottom Line
Retatrutide's side effect profile is reassuringly familiar. The GI effects — nausea, diarrhoea, vomiting, constipation — are the same constellation seen with every GLP-1 medication, occurring at similar or even lower rates than semaglutide. The glucagon component adds a modest heart rate increase but also delivers unique benefits (energy expenditure, liver fat reduction) that no other drug offers.
The most important message: side effects are manageable, transient, and rarely lead to treatment discontinuation. For the vast majority of patients, the profound weight loss and metabolic benefits will far outweigh the temporary GI discomfort of the first few weeks.
Phase 3 data will refine this picture. Until then, patients considering weight management should explore currently available options in Malaysia — all of which have well-established safety profiles after years of clinical use.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any treatment, supplement regimen, or making changes to your health routine. Individual results may vary, and what works for others may not work for you.